1 week Ago By Defense World Staff
Norges Bank purchased a new position in shares of Artiva Biotherapeutics, Inc. (NASDAQ:ARTV – Free Report) in the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission. The fund purchased 30,000 shares of the company’s stock, valued at approximately $302,000.
Norges Bank owned about 0.12% of Artiva Biotherapeutics at the end of the most recent reporting period. Several other institutional investors and hedge funds have also made changes to their positions in ARTV.
BNP Paribas Financial Markets acquired a new stake in shares of Artiva Biotherapeutics during the 3rd quarter worth about $42,000. China Universal Asset Management Co. Ltd.
purchased a new position in Artiva Biotherapeutics in the fourth quarter valued at approximately $52,000. JPMorgan Chase & Co. acquired a new stake in Artiva Biotherapeutics during the third quarter worth approximately $166,000.
Barclays PLC purchased a new stake in shares of Artiva Biotherapeutics during the 3rd quarter worth approximately $304,000. Finally, Charles Schwab Investment Management Inc. boosted its holdings in shares of Artiva Biotherapeutics by 8.
0% in the 4th quarter. Charles Schwab Investment Management Inc. now owns 43,526 shares of the company’s stock valued at $439,000 after buying an additional 3,233 shares in the last quarter.
Artiva Biotherapeutics Stock PerformanceNASDAQ ARTV opened at $1.98 on Friday. The firm’s fifty day moving average is $3.
90 and its two-hundred day moving average is $8.45. Artiva Biotherapeutics, Inc.
has a one year low of $1.78 and a one year high of $17.31.
Analyst Upgrades and DowngradesSeveral equities research analysts recently commented on the stock. HC Wainwright reiterated a “buy” rating and set a $20.00 price target on shares of Artiva Biotherapeutics in a research note on Wednesday, March 26th.
Cantor Fitzgerald cut their target price on Artiva Biotherapeutics from $23.00 to $20.00 and set an “overweight” rating on the stock in a research report on Tuesday, March 25th.
Wedbush reissued an “outperform” rating and issued a $18.00 target price on shares of Artiva Biotherapeutics in a report on Tuesday, March 25th. Finally, Needham & Company LLC restated a “buy” rating and set a $23.
00 price target on shares of Artiva Biotherapeutics in a research note on Tuesday, April 8th. Six equities research analysts have rated the stock with a buy rating, According to MarketBeat.com, the stock has a consensus rating of “Buy” and a consensus target price of $20.
40.Get Our Latest Stock Report on Artiva BiotherapeuticsAbout Artiva Biotherapeutics (Free Report)Artiva Biotherapeutics, Inc, a clinical-stage biotechnology company, focuses on developing natural killer (NK) cell-based therapies for patients suffering from autoimmune diseases and cancers. The company’s lead product candidate is AB-101, an off-the-shelf NK cell therapy for patients with autoimmune diseases and cancers, such as lupus nephritis, rheumatoid arthritis, pemphigus vulgaris, the anti-neutrophil cytoplasmic antibody-associated vasculitis subtypes granulomatosis with polyangiitis/microscopic polyangiitis, systemic lupus erythematosus, and B-cell-non-Hodgkin lymphoma.
Read MoreFive stocks we like better than Artiva BiotherapeuticsHow to Start Investing in Real EstateRobinhood Strategies Could Be a Game-Changer for Young InvestorsLearn Technical Analysis Skills to Master the Stock MarketAre These 3 Retail Stocks Oversold or Really in Trouble?What is the Euro STOXX 50 Index?IONQ & RGTI Join DARPA Quantum Initiative: High Stakes Are Ahead.
